These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 29893356)

  • 21. Meta-analysis of everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease: final 3-year results of the SPIRIT clinical trials program (Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions).
    Dangas GD; Serruys PW; Kereiakes DJ; Hermiller J; Rizvi A; Newman W; Sudhir K; Smith RS; Cao S; Theodoropoulos K; Cutlip DE; Lansky AJ; Stone GW
    JACC Cardiovasc Interv; 2013 Sep; 6(9):914-22. PubMed ID: 24050859
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Final 5-year outcomes from the Endeavor zotarolimus-eluting stent clinical trial program: comparison of safety and efficacy with first-generation drug-eluting and bare-metal stents.
    Kandzari DE; Leon MB; Meredith I; Fajadet J; Wijns W; Mauri L
    JACC Cardiovasc Interv; 2013 May; 6(5):504-12. PubMed ID: 23602459
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Randomized comparison of everolimus-eluting stents and sirolimus-eluting stents in patients with ST elevation myocardial infarction: RACES-MI trial.
    Di Lorenzo E; Sauro R; Varricchio A; Capasso M; Lanzillo T; Manganelli F; Carbone G; Lanni F; Pagliuca MR; Stanco G; Rosato G; Suryapranata H; De Luca G
    JACC Cardiovasc Interv; 2014 Aug; 7(8):849-56. PubMed ID: 25147029
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of newer-generation drug-eluting with bare-metal stents in patients with acute ST-segment elevation myocardial infarction: a pooled analysis of the EXAMINATION (clinical Evaluation of the Xience-V stent in Acute Myocardial INfArcTION) and COMFORTABLE-AMI (Comparison of Biolimus Eluted From an Erodible Stent Coating With Bare Metal Stents in Acute ST-Elevation Myocardial Infarction) trials.
    Sabaté M; Räber L; Heg D; Brugaletta S; Kelbaek H; Cequier A; Ostojic M; Iñiguez A; Tüller D; Serra A; Baumbach A; von Birgelen C; Hernandez-Antolin R; Roffi M; Mainar V; Valgimigli M; Serruys PW; Jüni P; Windecker S
    JACC Cardiovasc Interv; 2014 Jan; 7(1):55-63. PubMed ID: 24332419
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Usefulness of Post-coronary Dilation to Prevent Recurrent Myocardial Infarction in Patients Treated With Percutaneous Coronary Intervention for Acute Coronary Syndrome (from the BASE ACS Trial).
    Karjalainen PP; Niemelä M; Laine M; Airaksinen JK; Ylitalo A; Nammas W
    Am J Cardiol; 2017 Feb; 119(3):345-350. PubMed ID: 27887689
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Two-year clinical outcomes of patients with overlapping second-generation drug-eluting stents for treatment of long coronary artery lesions: comparison of everolimus-eluting stents with resolute zotarolimus-eluting stents.
    Li XT; Sun H; Zhang DP; Xu L; Ni ZH; Xia K; Liu Y; Chi YH; He JF; Li WM; Wang HS; Wang LF; Yang XC
    Coron Artery Dis; 2014 Aug; 25(5):405-11. PubMed ID: 24584031
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of everolimus- and paclitaxel-eluting stents in patients with acute and stable coronary syndromes: pooled results from the SPIRIT (A Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System) and COMPARE (A Trial of Everolimus-Eluting Stents and Paclitaxel-Eluting Stents for Coronary Revascularization in Daily Practice) Trials.
    Planer D; Smits PC; Kereiakes DJ; Kedhi E; Fahy M; Xu K; Serruys PW; Stone GW
    JACC Cardiovasc Interv; 2011 Oct; 4(10):1104-15. PubMed ID: 22017936
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impact of current smoking on 2-year clinical outcomes between durable-polymer-coated stents and biodegradable-polymer-coated stents in acute myocardial infarction after successful percutaneous coronary intervention: Data from the KAMIR.
    Kim YH; Her AY; Jeong MH; Kim BK; Hong SJ; Shin DH; Kim JS; Ko YG; Choi D; Hong MK; Jang Y
    PLoS One; 2018; 13(10):e0205046. PubMed ID: 30289945
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Can "Hybrid stent implantation" improve long-term safety without adversely affecting efficacy when treating multilesion coronary artery disease in the drug-eluting stent era?
    Zhang D; Xu B; Dou KF; Yang YJ; Chen JL; Qiao SB; Wang Y; Li JJ; Qin XW; Yao M; Liu HB; Wu YJ; Chen J; Yuan JQ; You SJ; Li W; Gao RL
    Chin Med J (Engl); 2013; 126(9):1612-7. PubMed ID: 23652038
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long-term efficacy and safety of drug-eluting stent implantation for patients with multiple coronary chronic total occlusions.
    Zhang J; Han YL; Li Y; Wang SL; Jing QM; Wang XZ; Ma YY; Luan B; Wang G; Wang B
    Chin Med J (Engl); 2010 Apr; 123(7):789-93. PubMed ID: 20497665
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-term outcome after drug-eluting versus bare-metal stent implantation in patients with ST-segment elevation myocardial infarction: 5 years follow-up from the randomized DEDICATION trial (Drug Elution and Distal Protection in Acute Myocardial Infarction).
    Holmvang L; Kelbæk H; Kaltoft A; Thuesen L; Lassen JF; Clemmensen P; Kløvgaard L; Engstrøm T; Bøtker HE; Saunamäki K; Krusell LR; Jørgensen E; Tilsted HH; Christiansen EH; Ravkilde J; Køber L; Kofoed KF; Terkelsen CJ; Helqvist S
    JACC Cardiovasc Interv; 2013 Jun; 6(6):548-53. PubMed ID: 23683734
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impact of ultra-long second-generation drug-eluting stent implantation.
    Honda Y; Muramatsu T; Ito Y; Sakai T; Hirano K; Yamawaki M; Araki M; Kobayashi N; Takimura H; Sakamoto Y; Mouri S; Tsutumi M; Takama T; Takafuji H; Tokuda T; Makino K
    Catheter Cardiovasc Interv; 2016 Feb; 87(2):E44-53. PubMed ID: 26010548
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of Durable-Polymer- and Biodegradable-Polymer-Based Newer-Generation Drug-Eluting Stents in Patients with Acute Myocardial Infarction and Prediabetes After Successful Percutaneous Coronary Intervention.
    Kim YH; Her AY; Jeong MH; Kim BK; Hong SJ; Kim S; Ahn CM; Kim JS; Ko YG; Choi D; Hong MK; Jang Y
    Int Heart J; 2020 Jul; 61(4):673-684. PubMed ID: 32684595
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Second-generation everolimus-eluting stents versus first-generation sirolimus-eluting stents in acute myocardial infarction. 1-year results of the randomized XAMI (XienceV Stent vs. Cypher Stent in Primary PCI for Acute Myocardial Infarction) trial.
    Hofma SH; Brouwer J; Velders MA; van't Hof AW; Smits PC; Queré M; de Vries CJ; van Boven AJ
    J Am Coll Cardiol; 2012 Jul; 60(5):381-7. PubMed ID: 22835668
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-term Outcomes of Primary Percutaneous Coronary Intervention with Second-generation Drug-eluting Stents in ST-elevation Myocardial Infarction Patients Caused by Very Late Stent Thrombosis.
    He C; Ma YL; Wang CS; Jiang L; Zhang JH; Yao Y; Tang XF; Xu B; Gao RL; Yuan JQ
    Chin Med J (Engl); 2017 Apr; 130(8):929-935. PubMed ID: 28397722
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Deployment of drug-eluting stents for isolated proximal lad disease is associated with lower major adverse cardiac events and no increase in stent thrombosis when compared with bare metal stents: a 5-year observational cohort study.
    Jones DA; Rathod KS; Gallagher S; Weerackody R; Knight CJ; Rothman MT; Mathur A; Jain AK; Timmis AD; Wragg A
    Catheter Cardiovasc Interv; 2013 May; 81(6):E237-44. PubMed ID: 22707383
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Routine angiographic follow-up versus clinical follow-up in patients with diabetes following percutaneous coronary intervention with drug-eluting stents in Korean population.
    Kim YH; Her AY; Choi BG; Choi SY; Byun JK; Park Y; Baek MJ; Ryu YG; Mashaly A; Jang WY; Kim W; Park EJ; Choi JY; Na JO; Choi CU; Lim HE; Kim EJ; Park CG; Seo HS; Rha SW
    Diabetes Res Clin Pract; 2018 Apr; 138():138-148. PubMed ID: 29428458
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Five-year clinical outcomes in patients with diabetes mellitus treated with polymer-free sirolimus- and probucol-eluting stents versus second-generation zotarolimus-eluting stents: a subgroup analysis of a randomized controlled trial.
    Harada Y; Colleran R; Kufner S; Giacoppo D; Rheude T; Michel J; Cassese S; Ibrahim T; Laugwitz KL; Kastrati A; Byrne RA;
    Cardiovasc Diabetol; 2016 Sep; 15(1):124. PubMed ID: 27586678
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-Term Outcomes of Biodegradable Versus Second-Generation Durable Polymer Drug-Eluting Stent Implantations for Myocardial Infarction.
    Choe JC; Cha KS; Lee JG; Kim J; Shin JY; Ahn J; Park JS; Lee HW; Oh JH; Choi JH; Lee HC; Hong TJ; Jeong MH;
    JACC Cardiovasc Interv; 2020 Jan; 13(1):97-111. PubMed ID: 31918948
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Safety and Efficacy of Everolimus- Versus Sirolimus-Eluting Stents: 5-Year Results From SORT OUT IV.
    Jensen LO; Thayssen P; Christiansen EH; Maeng M; Ravkilde J; Hansen KN; Hansen HS; Krusell L; Kaltoft A; Tilsted HH; Berencsi K; Junker A; Lassen JF;
    J Am Coll Cardiol; 2016 Feb; 67(7):751-62. PubMed ID: 26892409
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.